CL2008003545A1 - Compuestos derivados del acido [(imidazol-1-il)-1-hidroxi-1-fosfono-etil]-fosfonico; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de una resorcion osea excesiva o inapropiada o de una enfermedad causada por una prenilacion excesiva de proteinas objetivo. - Google Patents
Compuestos derivados del acido [(imidazol-1-il)-1-hidroxi-1-fosfono-etil]-fosfonico; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de una resorcion osea excesiva o inapropiada o de una enfermedad causada por una prenilacion excesiva de proteinas objetivo.Info
- Publication number
- CL2008003545A1 CL2008003545A1 CL2008003545A CL2008003545A CL2008003545A1 CL 2008003545 A1 CL2008003545 A1 CL 2008003545A1 CL 2008003545 A CL2008003545 A CL 2008003545A CL 2008003545 A CL2008003545 A CL 2008003545A CL 2008003545 A1 CL2008003545 A1 CL 2008003545A1
- Authority
- CL
- Chile
- Prior art keywords
- excessive
- phosphono
- imidazol
- hydroxy
- ethyl
- Prior art date
Links
- 208000006386 Bone Resorption Diseases 0.000 title abstract 2
- 208000020084 Bone disease Diseases 0.000 title abstract 2
- 230000024279 bone resorption Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 title abstract 2
- 230000013823 prenylation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos derivados de ácido [(imidazol-1-il)-1-hidroxi-1-fosfono-etil]-fosfónico; método de preparación; composición farmacéutica; y uso para el tratamiento de una resorción ósea excesiva o inapropiada o de una enfermedad causada por una prenilación excesiva de proteínas objetivo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07122016 | 2007-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008003545A1 true CL2008003545A1 (es) | 2009-06-05 |
Family
ID=39154111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008003545A CL2008003545A1 (es) | 2007-11-30 | 2008-11-28 | Compuestos derivados del acido [(imidazol-1-il)-1-hidroxi-1-fosfono-etil]-fosfonico; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de una resorcion osea excesiva o inapropiada o de una enfermedad causada por una prenilacion excesiva de proteinas objetivo. |
Country Status (24)
Country | Link |
---|---|
US (2) | US7977323B2 (es) |
EP (1) | EP2225252B1 (es) |
JP (1) | JP5244917B2 (es) |
KR (1) | KR20100092035A (es) |
CN (1) | CN101835787A (es) |
AR (1) | AR069437A1 (es) |
AU (1) | AU2008328797B2 (es) |
BR (1) | BRPI0819902A2 (es) |
CA (1) | CA2701516A1 (es) |
CL (1) | CL2008003545A1 (es) |
CO (1) | CO6280421A2 (es) |
CR (1) | CR11362A (es) |
EA (1) | EA201000860A1 (es) |
EC (1) | ECSP10010321A (es) |
ES (1) | ES2386851T3 (es) |
IL (1) | IL204657A0 (es) |
MA (1) | MA31895B1 (es) |
MX (1) | MX2010005786A (es) |
NZ (1) | NZ584219A (es) |
PE (1) | PE20091038A1 (es) |
TN (1) | TN2010000138A1 (es) |
TW (1) | TW200932248A (es) |
WO (1) | WO2009068567A1 (es) |
ZA (1) | ZA201001992B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102046152A (zh) * | 2008-04-04 | 2011-05-04 | 诺瓦提斯公司 | 含有双膦酸盐的药物组合物 |
US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US8399023B2 (en) | 2009-07-31 | 2013-03-19 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US9290526B2 (en) | 2010-05-28 | 2016-03-22 | The Royal Institution For The Advancement Of Learning/Mcgill University | Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
US8816082B2 (en) | 2010-05-28 | 2014-08-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
CN102659840B (zh) * | 2012-05-10 | 2013-08-14 | 苏州普瑞诺药物技术有限公司 | 咪唑双膦酸类化合物及其可药用盐及药物用途 |
WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
EP3698797A1 (en) | 2017-10-16 | 2020-08-26 | Tsinghua University | Mevalonic acid pathway inhibitor and pharmaceutical composition thereof |
CN112980809B (zh) * | 2021-03-17 | 2023-04-11 | 云南中烟工业有限责任公司 | 一种烟草法尼基焦磷酸合酶基因及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL84497A (en) | 1986-11-21 | 1994-10-21 | Ciba Geigy Ag | History 2-) Imidazol-1-yl (ethane-1,1-diphosphonic acid, their preparation and pharmaceutical preparations containing them |
ATE119777T1 (de) * | 1991-02-26 | 1995-04-15 | Procter & Gamble Pharma | Behandlungsmethoden für osteoporose. |
GB9324143D0 (en) | 1993-11-24 | 1994-01-12 | Schering Agrochemicals Ltd | Triazole phosphonate pesticides |
GB0029018D0 (en) * | 2000-11-28 | 2001-01-10 | Strakan Group Plc | Dermatological formulations |
GB0029111D0 (en) * | 2000-11-29 | 2001-01-10 | Novartis Ag | Organic compounds |
WO2006039721A2 (en) | 2004-10-08 | 2006-04-13 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
US8012949B2 (en) | 2004-10-08 | 2011-09-06 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS |
AU2007304205A1 (en) | 2006-10-05 | 2008-04-10 | Novartis Ag | Pharmaceutical compositions comprising bisphosphonates |
CN101679422A (zh) | 2007-03-28 | 2010-03-24 | 阵列生物制药公司 | 作为受体酪氨酸激酶抑制剂的咪唑并[1,2-a]吡啶化合物 |
-
2008
- 2008-11-26 US US12/323,696 patent/US7977323B2/en not_active Expired - Fee Related
- 2008-11-26 AU AU2008328797A patent/AU2008328797B2/en not_active Ceased
- 2008-11-26 MX MX2010005786A patent/MX2010005786A/es active IP Right Grant
- 2008-11-26 KR KR1020107014395A patent/KR20100092035A/ko not_active Application Discontinuation
- 2008-11-26 JP JP2010535369A patent/JP5244917B2/ja active Active
- 2008-11-26 NZ NZ584219A patent/NZ584219A/en not_active IP Right Cessation
- 2008-11-26 BR BRPI0819902-7A patent/BRPI0819902A2/pt not_active IP Right Cessation
- 2008-11-26 CN CN200880112351A patent/CN101835787A/zh active Pending
- 2008-11-26 EA EA201000860A patent/EA201000860A1/ru unknown
- 2008-11-26 EP EP08854485A patent/EP2225252B1/en active Active
- 2008-11-26 CA CA2701516A patent/CA2701516A1/en not_active Abandoned
- 2008-11-26 WO PCT/EP2008/066245 patent/WO2009068567A1/en active Application Filing
- 2008-11-26 ES ES08854485T patent/ES2386851T3/es active Active
- 2008-11-27 AR ARP080105163A patent/AR069437A1/es active IP Right Grant
- 2008-11-27 PE PE2008001990A patent/PE20091038A1/es not_active Application Discontinuation
- 2008-11-28 CL CL2008003545A patent/CL2008003545A1/es unknown
- 2008-11-28 TW TW097146484A patent/TW200932248A/zh unknown
-
2010
- 2010-03-19 ZA ZA2010/01992A patent/ZA201001992B/en unknown
- 2010-03-22 IL IL204657A patent/IL204657A0/en unknown
- 2010-03-26 TN TNP2010000138A patent/TN2010000138A1/fr unknown
- 2010-04-09 CR CR11362A patent/CR11362A/es unknown
- 2010-05-26 CO CO10063351A patent/CO6280421A2/es not_active Application Discontinuation
- 2010-05-31 MA MA32880A patent/MA31895B1/fr unknown
- 2010-06-30 EC EC2010010321A patent/ECSP10010321A/es unknown
-
2011
- 2011-05-26 US US13/116,671 patent/US20110224173A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ECSP10010321A (es) | 2010-08-31 |
EP2225252B1 (en) | 2012-06-27 |
WO2009068567A1 (en) | 2009-06-04 |
US7977323B2 (en) | 2011-07-12 |
JP5244917B2 (ja) | 2013-07-24 |
US20110224173A1 (en) | 2011-09-15 |
TN2010000138A1 (en) | 2011-09-26 |
CO6280421A2 (es) | 2011-05-20 |
PE20091038A1 (es) | 2009-08-19 |
EP2225252A1 (en) | 2010-09-08 |
AU2008328797A1 (en) | 2009-06-04 |
BRPI0819902A2 (pt) | 2015-05-19 |
MA31895B1 (fr) | 2010-12-01 |
TW200932248A (en) | 2009-08-01 |
CN101835787A (zh) | 2010-09-15 |
ES2386851T3 (es) | 2012-09-03 |
KR20100092035A (ko) | 2010-08-19 |
AR069437A1 (es) | 2010-01-20 |
ZA201001992B (en) | 2010-12-29 |
EA201000860A1 (ru) | 2010-12-30 |
NZ584219A (en) | 2012-03-30 |
CA2701516A1 (en) | 2009-06-04 |
JP2011504908A (ja) | 2011-02-17 |
MX2010005786A (es) | 2010-06-09 |
US20090143337A1 (en) | 2009-06-04 |
CR11362A (es) | 2010-06-14 |
IL204657A0 (en) | 2010-11-30 |
AU2008328797B2 (en) | 2011-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008003545A1 (es) | Compuestos derivados del acido [(imidazol-1-il)-1-hidroxi-1-fosfono-etil]-fosfonico; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de una resorcion osea excesiva o inapropiada o de una enfermedad causada por una prenilacion excesiva de proteinas objetivo. | |
CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
WO2015009991A8 (en) | Methods, systems, and compositions for promoting bone growth | |
EA201390772A1 (ru) | Новые соли и полиморфные формы афатиниба | |
DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
MX338088B (es) | Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf). | |
EA201100873A1 (ru) | Пиридилоксииндолы - ингибиторы vegf-r2 и их применение для лечения заболевания | |
MX2010009743A (es) | Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami | |
SV2009003299A (es) | Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa | |
EA201290131A1 (ru) | Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний | |
BR112012022211A2 (pt) | composto. composição farmacêutica, método de tratamento de uma doença meidada por h4r, método de inibição de h4h, método de tratamento da dor ou inflamação resultante de cirurgia de catarata, método para atingir um efeito em um paciente e uso de uma composto | |
EA201692506A3 (ru) | Ингибиторы репликации вирусов гриппа | |
CL2008002089A1 (es) | Compuesto para la regeneracion de tejidos que comprende al menos una sustancia derivada de sangre y acido hialuronico y/o al menos un compuesto derivado de acido hialuronico; metodo para la prepararcion de dicho compuesto. | |
EA201101192A1 (ru) | Фармацевтическая композиция, включающая производные глюкопиранозилдифенилметана, фармацевтическая дозированная форма, содержащая указанные производные, способ их получения и применения для улучшения гликемического контроля у пациентов | |
CR20200334A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
IL195142A (en) | Processed arylaimidazolone and triazolone, their preparation process, pharmaceutical preparations containing them for the treatment or prevention of diseases | |
CL2010001260A1 (es) | Composicion farmaceutica que comprende una sal de estroncio y vitamina d y una ciclodextrina, donde la relacion masica entre la cantidad de vitamina d y la cantidad de ciclodextrina esta comprendida entre 1/40 y 1/800, util para tratar o prevenir osteoporosis. | |
CL2008000021A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer. | |
IL192557A (en) | Imidazole derivatives are conserved and used as ptpase inhibitors | |
MY164864A (en) | Indenone derivative and pharmaceutical composition comprising same | |
EA200970532A1 (ru) | Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола | |
MX2014006601A (es) | Formulaciones de moxidectina inyectables de larga accion y formas de cristal de moxidectina novedosas. | |
EA201270116A1 (ru) | Применение лекарственной формы для наружного нанесения, содержащей хитозан | |
BRPI0914454A2 (pt) | "composição para o tratamento do tecido epitelial" | |
EP4000609A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF BONE DISEASES |